Lupin Limited has announced a strategic collaboration with TB Alliance, a nonprofit drug developer, to advance the clinical development and commercialization of the investigational drug Telacebec (formerly known as Q203). This partnership aims to provide advanced treatment options for patients affected by multiple mycobacterial diseases, including tuberculosis (TB), leprosy, and Buruli ulcer. Under the agreement, TB Alliance will continue to lead the development process, while Lupin will contribute its expertise in global manufacturing, regulatory affairs, and supply chain management to ensure worldwide access to Telacebec. Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU at Lupin, stated that the collaboration underscores Lupin's commitment to improving patient outcomes in areas of significant unmet medical need. He added that by leveraging Lupin's manufacturing scale and distribution capabilities, along with TB Alliance's drug development expertise, the goal is to enable timely and equitable access to Telacebec. Mel Spigelman, MD, President and CEO of TB Alliance, highlighted that Telacebec represents innovative science with the potential to transform treatment for neglected diseases. He emphasized that the partnership with Lupin combines scientific expertise with global manufacturing and access capabilities to advance the compound as quickly and responsibly as possible, aiming to deliver better treatment options globally.
